What are the current guidelines for the management and treatment options available for patients diagnosed with SMA?

The provided UK guideline context does not contain specific information on the management and treatment options available for patients diagnosed with spinal muscular atrophy (SMA).

The documents supplied cover guidelines for:

• Spasticity in under 19s, which outlines principles of care such as access to a network of healthcare professionals, individualized and goal-focused management programmes, and assessment of the impact of spasticity ¹.
• Axial spondyloarthritis (including ankylosing spondylitis), detailing assessment of response to anti-TNF therapy, cardiovascular and osteoporosis risk, and management of uncontrolled symptoms or treatment failure, including physiotherapy and exercise programmes ².
• Motor neurone disease (MND), which includes recommendations for managing muscle cramps, stiffness, and spasticity with various medications (e.g., quinine, baclofen, tizanidine, dantrolene, gabapentin), exercise programmes, and addressing saliva problems ³. It also mentions riluzole as a disease-modifying treatment for the amyotrophic lateral sclerosis form of MND, and the provision of equipment and adaptations for daily living and mobility ³.
• Multiple sclerosis, covering optimal management of comorbid conditions, vaccination, pregnancy, annual review, and social care needs ⁴.

While Spinal Muscular Atrophy is a type of motor neurone disease, the specific guidelines provided for MND focus on amyotrophic lateral sclerosis and general symptomatic management, without direct mention or specific guidance for SMA ³.